ライフサイエンスコーパス: end-stage liver disease

1 e mainstay of managing patients with AUD and end-stage liver disease.

2 silent disease, and eventually progresses to end-stage liver disease.

3 in treating kidney failure in patients with end-stage liver disease.

4 cirrhosis, liver and kidney transplants, and end-stage liver disease.

5 challenges to using these cells in treating end-stage liver disease.

6 ents such as LTx-recipients or patients with end-stage liver disease.

7 er disease, nonalcoholic steatohepatitis, or end-stage liver disease.

8 t also medium-term survival of patients with end-stage liver disease.

9 elomere attrition is a major risk factor for end-stage liver disease.

10 gan transplantation (IFOT) for patients with end-stage liver disease.

11 sis does not resolve with FO may progress to end-stage liver disease.

12 Hepatic PP-IX accumulation may lead to end-stage liver disease.

13 py exists to halt disease progression toward end-stage liver disease.

14 HCV infection may develop into HCC as an end-stage liver disease.

15 lution of cholestasis and rarely progress to end-stage liver disease.

16 tients required transplantation or died from end-stage liver disease.

17 s a functional renal impairment complicating end-stage liver disease.

18 uce its diagnostic accuracy in patients with end-stage liver disease.

19 ain asymptomatic until onset of cirrhosis or end-stage liver disease.

20 for liver transplantation even if they have end-stage liver disease.

21 new therapeutic strategies for patients with end-stage liver diseases.

22 cirrhosis different from other etiologies of end-stage liver disease?

23 to be first-time recipients with a model for end-stage liver disease 15-34, without primary biliary c

24 as LDLT recipients had lower mean model for end-stage liver disease (15.5 vs 20.4) and fewer receive

25 Among HIV-infected, model of end-stage liver disease (aHR, 1.04; P < 0.001), body mas

26 Four variables (Model for End-Stage Liver Disease, alpha-fetoprotein, Milan-Criter

27 seline prognostic scoring systems (Model for End-Stage Liver Disease and age, bilirubin, internationa

28 obiome alterations correlated with model for end-stage liver disease and Child-Pugh scores and organ

29 H cirrhosis currently are based on model for end-stage liver disease and Child-Pugh-Turcotte scores,

30 dex score, serum level of albumin, model for end-stage liver disease and Child-Turcotte-Pugh scores (

31 The admission model included Model for End-Stage Liver Disease and diabetes (c-statistic = 0.64

32 rsibility of renal failure for patients with end-stage liver disease and may be useful in the kidney

33 It is observed in up to 60% of patients with end-stage liver disease and portends a poor prognosis.

34 ednisolone therapy, independent of Model for End-Stage Liver Disease and white blood cell count (OR,

35 onic carriers are at high risk of developing end-stage liver diseases and hepatocellular carcinoma.

36 were detected and who were free of fibrosis, end-stage liver disease, and chronic hepatitis B at base

37 IDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease out

38 IDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease out

39 IDS-defining cancers, myocardial infarction, end-stage liver disease, and end-stage renal disease.

40 fter matching both groups for age, model for end-stage liver disease, and GRWR.

41 irus (HBV) infections can lead to cirrhosis, end-stage liver disease, and hepatocellular carcinoma.

42 ects of chronic infection include cirrhosis, end-stage liver disease, and hepatocellular carcinoma.

43 reduce the untoward effects of sequelae from end-stage liver disease, and to minimize the requirement

44 The Child Pugh score and Model for End Stage Liver Disease are utilized for surgical risk a

45 90% to 95% of patients with alcohol-related end-stage liver disease are never formally evaluated for

46 n of HBV through distinct clinical phases to end-stage liver disease are poorly understood.

47 tive role for HLA-G after LTX, but show that end-stage liver diseases are associated with HLA-G expre

48 lity following recurrence included model for end-stage liver disease at LT >23, time to recurrence, >

49 Matching was based on: age, sex, model for end-stage liver disease at the time of transplant, type

50 alysis of covariance, adjusted for model for end-stage liver disease at time of hospital admission, s

51 pediatric end-stage liver disease/model for end-stage liver disease at transplant for infants (29 ve

52 olume, LOS, biliary complications, Model for End-Stage Liver Disease at transplant, and hepatitis C v

53 the available options are greatly limited in end-stage liver disease because many GABA-Ergic drugs ca

54 ients and even more frequently in those with end-stage liver disease because of inadequate adherence

55 olangiopathy that progresses to fibrosis and end-stage liver disease by 2 years of age.

56 that nongenetic causes of hepcidin loss (eg, end-stage liver disease) can cause acquired forms of hem

57 However, end-stage liver disease caused by chronic Cryptosporidiu

58 Sixty-eight participants with end-stage liver disease (Child-Turcotte-Pugh score >=7 a

59 ermined along with the scores like model for end stage liver disease, child turcotte pugh were record

60 r North American Consortium for the Study of End-Stage Liver Disease cohort.

61 e North American Consortium for the Study of End-Stage Liver Disease consists of 16 tertiary-care hep

62 f acute kidney injury (AKI) in patients with end-stage liver disease constitutes one of the most chal

63 ance, has been demonstrated in patients with end-stage liver disease, defined as a contributor to dis

64 , age of the recipient, laboratory model for end-stage liver disease, donor risk index, period of tra

65 diabetes (27% vs. 37%; P = 0.02), model for end-stage liver disease era (68% vs. 82%; P = 0.0001), s

66 K transplants by 0.99 years in the Model for End-stage Liver Disease era and 1.71 years in the pre-Mo

67 ysis requirement, hepatitis C, and model for end-stage liver disease era transplantation but was not

68 es published between 2002 and 2016 (model of end-stage liver disease era).

69 ease era and 1.71 years in the pre-Model for End-stage Liver Disease era.

70 al brain activity in delirious patients with end stage liver disease (ESLD) is detected by fNIRS.

71 haring SLK transplant policy on outcomes for end-stage liver disease (ESLD) and end-stage renal disea

72 ycocalyx core protein, syndecan-1, occurs in end-stage liver disease (ESLD) and that it increases dur

73 End-stage liver disease (ESLD) caused by hepatitis C vir

74 identify a prognostic profile that predicts end-stage liver disease (ESLD) events including ascites,

75 End-stage liver disease (ESLD) is a major burden on publ

76 Patients with end-stage liver disease (ESLD) often have a high symptom

77 Patients with end-stage liver disease (ESLD) suffer from a high sympto

78 arting point, we analyzed the development of end-stage liver disease (ESLD), hepatocellular carcinoma

79 virus (HCV) is one of the leading causes of end-stage liver disease (ESLD), such as decompensated ci

80 ity of life (QoL) exhibited by patients with end-stage liver disease (ESLD), we studied the associati

81 and C (HCV) viruses are at increased risk of end-stage liver disease (ESLD).

82 mpare incidence rates between HCV groups for end-stage liver disease (ESLD; including hepatocellular

83 ad myocardial infarctions, 387 of 35 044 had end-stage liver disease events, and 255 of 35 620 had en

84 months, respectively) who received Model for End Stage Liver Disease exception listing for HCC from 2

85 Despite uniform HCC Model for End-Stage Liver Disease exception across height and sex,

86 ld be given to awarding additional Model for End-Stage Liver Disease exception points to these patien

87 thin the Milan criteria for whom a Model for End-Stage Liver Disease exception was approved were retr

88 s measured primarily by the use of model for end-stage liver disease excluding international normaliz

89 We evaluated 86 patients with end-stage liver disease for variants in an expanded pane

90 t was only significant in the high Model for End-Stage Liver Disease group (P < 0.001).

91 Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease >15 before being offered to loca

92 s of cirrhosis patients with higher Model of End-Stage Liver Disease (>15) showed significantly decre

93 al Condition Category 83), 2.55 (2.35-2.77); end-stage liver disease (Hierarchical Condition Category

94 us, encephalopathy, diabetes, high Model for End-stage Liver Disease, Hispanic race, older age and a

95 ransplantation is an effective treatment for end-stage liver disease; however, demand greatly outweig

96 = 1.895, 95% CI: 1.081-3.323) and model for end stage liver disease (HR = 1.054, 95% CI: 1.020-1.090

97 s were diabetes, chronic kidney disease, and end-stage liver disease (HR = 1.2, 95% CI = 1.0-1.4 when

98 ary atresia (BA) is the most common cause of end-stage liver disease in children and the primary indi

99 nt of preventive measures and treatments for end-stage liver disease in elderly patients.

100 Despite the increasing prevalence of end-stage liver disease in older adults, there is no con

101 CCM) is cardiac dysfunction in patients with end-stage liver disease in the absence of prior heart di

102 were found in patients with higher model for end-stage liver disease in the same disease group; and l

103 There were no differences in Model for End-Stage Liver Disease including serum sodium and Child

104 se of chronic liver disease that can lead to end-stage liver diseases, including cirrhosis and hepato

105 Their median model of end-stage liver disease, incorporating serum sodium scor

106 des (P = 0.02); independent of age, model of end-stage liver disease, incorporating serum sodium scor

107 th longer wait-time, higher rate of model of end-stage liver disease increase, and intermediate 90-da

108 The clinical picture of alcoholic end-stage liver disease is rendered extremely complex, a

109 Hepatitis C virus (HCV)-induced end-stage liver disease is the major indication for live

110 ic liver transplantation in the treatment of end-stage liver diseases, its therapeutic utility is sev

111 hosis with recurrent HE with MELD (Model for End-Stage Liver Disease) <17 on SOC were randomized 1:1

112 al fibrillation/flutter, syncope/presyncope, end-stage liver disease, malignancy, and anxiety.

113 Changes in the epidemiology of end-stage liver disease may lead to increased risk of dr

114 Gut dysbiosis characteristic of end-stage liver disease may predispose patients to intes

115 The complexity of end-stage liver disease may warrant more intensive care

116 (ALT), acute kidney injury (AKI), model for end stage liver disease (MELD) and septic shock are the

117 patients were also dichotomized by Model for End Stage Liver Disease (MELD) score (</=15 vs >15) and

118 er transplantation with laboratory Model for End-Stage Liver Disease (MELD) >/=12 at a single center

119 The Model for End-Stage Liver Disease (MELD) allocation system for liv

120 Since the Model for End-stage Liver Disease (MELD) allocation system was imp

121 ysfunction was determined based on model for end-stage liver disease (MELD) and Child-Pugh scores.

122 a parsimonious model consisting of Model for End-Stage Liver Disease (MELD) and LA at admission may p

123 cs: total mortalities, DSA-average model for end-stage liver disease (MELD) at transplant, DSA-averag

124 Mean model for end-stage liver disease (MELD) at transplantation was 22

125 ndication was defined as DC if the Model for End-Stage Liver Disease (MELD) at WL was >/=15 or hepato

126 nsplant for patients listed with a Model for End-Stage Liver Disease (MELD) between 22 and 27 will do

127 d the impact of this difference on Model for End-Stage Liver Disease (MELD) calculation.

128 Current Model for End-Stage Liver Disease (MELD) exception points provided

129 llular carcinoma (HCC) can receive Model for End-Stage Liver Disease (MELD) exception points to incre

130 nsplantation Network policy grants Model for End-Stage Liver Disease (MELD) exception points to patie

131 ients' disease severity, using the Model for End-Stage Liver Disease (MELD) in 8387 French patients w

132 The model for end-stage liver disease (MELD) is based on objective var

133 The Model for End-Stage Liver Disease (MELD) is used for clinical deci

134 with a median age of 64 years and Model for End-stage Liver Disease (MELD) MELD of 12.10 (25%) were

135 ellular carcinoma (HCC) additional Model for End-Stage Liver Disease (MELD) points is controversial d

136 Model for End-Stage Liver Disease (MELD) prioritization of liver r

137 re 35, of whom 4,599 (27.9%) had a Model for End-Stage Liver Disease (MELD) score >/=35.

138 at multivariate analysis included Model for End-Stage Liver Disease (MELD) score >10, and absence of

139 rence was highest in patients with Model for End-stage Liver Disease (MELD) score >=10.

140 isted for SLKT, stratified by base Model for End-Stage Liver Disease (MELD) score (<=20, 21-30, >30).

141 own by allocation or by laboratory model for end-stage liver disease (MELD) score (6-14, 15-24, 25-29

142 95) and performed well compared to Model for End-Stage Liver Disease (MELD) score (C-statistic, 0.72;

143 Model for End-stage Liver Disease (MELD) score (hazard ratio [HR],

144 group of patients with laboratory Model for End-Stage Liver Disease (MELD) score (labMELD) scores >=

145 Baseline Model for End-Stage Liver Disease (MELD) score alone (cut-off 18)

146 too sick." Our primary outcome was Model for End-Stage Liver Disease (MELD) score at waitlist removal

147 ; 95% CI, 1.13-4.30; P = .01), and Model for End-Stage Liver Disease (MELD) score greater than 9 (OR,

148 estimation of 90-day mortality by Model for End-Stage Liver Disease (MELD) score has improved wait l

149 The Model for End-Stage Liver Disease (MELD) score is predictive of tr

150 n nine adults with cirrhosis and a Model for End-Stage Liver Disease (MELD) score of 10-16 (ISRCTN 10

151 on in patients with cirrhosis with Model for End-Stage Liver Disease (MELD) score of 12 or less.

152 - 10 years, 63% men) with a median Model for End-Stage Liver Disease (MELD) score of 17 (interquartil

153 and recipients frequently attain a Model for End-Stage Liver Disease (MELD) score of 40 or higher bef

154 re high-acuity with median biologic model of end-stage liver disease (MELD) score of, 35 for dCLKT an

155 The Model for End-Stage Liver Disease (MELD) score predicts higher tra

156 Model for End-Stage Liver Disease (MELD) score transiently worsene

157 mortality or removal according to model for end-stage liver disease (MELD) score vs ACLF category.

158 as 3.8% (1.5, 6.9), and the median Model for End-Stage Liver Disease (MELD) score was 11.6 (9.4, 14.0

159 Median Model for End-Stage Liver Disease (MELD) score was 23 [17, 30] and

160 adult patients with cirrhosis and Model for End-Stage Liver Disease (MELD) score within 3 months of

161 artile range (IQR), 47-62]; median model for end-stage liver disease (MELD) score, 15 [IQR, 11-18]).

162 ir age, body mass index, diabetes, model for end-stage liver disease (MELD) score, and need for dialy

163 g HCV often improves our patients' model for end-stage liver disease (MELD) score, decreasing costs,

164 e-LT BNP concentration, adjusted on model of end-stage liver disease (MELD) score, was an independent

165 Model for End-Stage Liver Disease (MELD) score-based liver transpl

166 ver disease patients regardless of Model for End-stage Liver Disease (MELD) score.

167 ered regionally to candidates with Model for End-Stage Liver Disease (MELD) scores >/=35 before being

168 Using the serial Model for End-Stage Liver Disease (MELD) scores recorded in the Un

169 splantation with much lower actual Model for End-Stage Liver Disease (MELD) scores than patients with

170 sion patterns of 123 genes and the model for end-stage liver disease (MELD) scores to assign patients

171 Child-Turcotte-Pugh (CTP) and Model for End-stage Liver Disease (MELD) scores were calculated.

172 he effect of therapy on changes in model for end-stage liver disease (MELD) scores were derived from

173 R patients were younger; had lower Model for End-stage Liver Disease (MELD) scores, AFP levels, and n

174 lic hepatitis (AH) correlates with Model for End-Stage Liver Disease (MELD) scores, biomarkers are cr

175 om pre-LT treatment based on their Model for End-Stage Liver Disease (MELD) scores.

176 rtality not well quantified by the Model for End-Stage Liver Disease (MELD) Sodium (MELDNa) score.

177 after stratifying patients by the Model for End-Stage Liver Disease (MELD) with a cutoff at 15 (<15

178 subgroup analysis by baseline GFR, model for end-stage liver disease (MELD), age, sex, race, and diab

179 Penn to the Mayo Risk Score (MRS), Model for End-Stage Liver Disease (MELD), Model for End-Stage Live

180 ceptance did not vary by candidate model for end-stage liver disease (MELD), the short-term risk peri

181 ates and retrospectively estimated Model for End-Stage Liver Disease (MELD)-adjusted DDLT rates using

182 On multivariate analysis, high Model for End-Stage Liver Disease (MELD; odds ratio [OR], 1.10; co

183 verage donor age and the advent of Model for End-stage Liver Diseases (MELD) score-based allocation c

184 ed by joint-effect model (based on Model for End-Stage Liver Disease [MELD] and Lille scores).

185 nsplanting higher risk recipients (Model for End-Stage Liver Disease [MELD] score >/=35, inpatient or

186 e, 50.4 +/- 11.8 years; 84% males; Model for End-Stage Liver Disease [MELD], 19.9 +/- 9.9), 36% had A

187 npatients, 63% were male patients, model for end-stage liver disease (MELDNa) was 32, and follow up w

188 allocation led to decreased median pediatric end-stage liver disease/model for end-stage liver diseas

189 bstructive cholangiopathy that progresses to end-stage liver disease, often requiring transplantation

190 storically, cirrhosis from PNALD resulted in end-stage liver disease, often requiring transplantation

191 ple in the United States, and often leads to end-stage liver disease or death.

192 with prednisolone, independent of model for end-stage liver disease or Lille score (OR, 2.46; 95% CI

193 p = 0.001) or after adjusting for Model for End-stage Liver Disease or Sequential Organ Failure Asse

194 IDS-defining cancers, myocardial infarction, end-stage liver disease, or end-stage renal disease outc

195 nfarction, stroke, end-stage renal diseases, end-stage liver diseases, or death.

196 k), but the Lille (P < 0.0001) and Model for End-Stage Liver Disease (P < 0.0001) scores were indepen

197 Despite HCV cure, 12 end-stage liver disease participants required subsequent

198 enter study included a cohort of consecutive end-stage liver disease patients with indications for LT

199 ational children with status 1B or Model for End-Stage Liver Disease/Pediatric End-Stage Liver Diseas

200 6 mg/dL); P < 0.001], and a higher pediatric end-stage liver disease (PELD) score [22 (14, 25) compar

201 The current pediatric end-stage liver disease (PELD) score underestimates pedi

202 ell-established markers, including Pediatric End-Stage Liver Disease (PELD) score.

203 ciated liver fibrosis is a critical step for end-stage liver disease progression.

204 n with 4 DSA factors: median match model for end-stage liver disease, proportion of white deaths out

205 The discharge model included Model for End-Stage Liver Disease, proton pump inhibitor use, and

206 but not in the placebo group, the Model for End-Stage Liver Disease reduced from 24.6 +/- 3.9 to 19.

207 ed patients develop fibrosis and progress to end-stage liver disease requiring liver transplantation

208 ster of differentiation 34+HSCs and Model of End-Stage Liver Disease (rho = -0.582, P < 0.001) and Ch

209 to the severity of liver disease (Model for End-Stage Liver Disease, rho = 0.45, P < 0.001), the deg

210 A pediatric end -stage liver disease score >=40, postoperative hospi

211 an age was 51.2 years; 48.0% had a Model for End-Stage Liver Disease score >/=20.

212 impairment (Child-Pugh class C or model for end-stage liver disease score >=19) were eligible.

213 R, 0.29; 95% CI, 0.03-0.99), and a model for end-stage liver disease score >=25 (HR, 0.26; 95% CI, 0.

214 tion, or ablation and a calculated model for end-stage liver disease score <15 at HCC diagnosis.

215 0.87 vs. 0.85) and was better than Model for End-Stage Liver Disease score (C-statistic 0.76).

216 onse rates, LT costs, and baseline Model for End-Stage Liver Disease score (DCC analysis only).

217 (HR, 1.51; 1.08-2.12), and a high Model for End-stage Liver Disease score (HR, 1.02; 1.00-1.04).

218 nfidence interval [CI], 2.1-13.8), Model for End-Stage Liver Disease score (odds ratio, 1.11; 95% CI,

219 liver stiffness (P < 0.001), worse Model for End-Stage Liver Disease score (P < 0.001), more portosys

220 correlated significantly with the Model for End-Stage Liver Disease score (r = -0.39, P < 0.05), fas

221 rage Child score 8.3 (+/-1.3), and Model for End-Stage Liver Disease score 11.7 (+/-3.9).

222 +/- 8 years) were analyzed (median Model for End-Stage Liver Disease score 20).

223 (Child-Turcotte-Pugh score >=7 and Model for End-Stage Liver Disease score 6-29) were enrolled, 26 ha

224 ed after the implementation of the model for end-stage liver disease score and a concomitant increase

225 interval from LRT to LT, and lower model for end-stage liver disease score and maximum tumor diameter

226 e 88 patients transplanted, median model for end-stage liver disease score at LT was 7 ((interquartil

227 The median age, body weight, and pediatric end-stage liver disease score at the time of transplant

228 LD had a significantly higher mean Model for End-Stage Liver Disease score at time of waitlist regist

229 gorized into three groups based on Model for End-Stage Liver Disease score at transplant: lower-score

230 everity of liver disease including Model for End-Stage Liver Disease score compared to middle aged an

231 n were acquisition of CRE post-LT, Model for End-Stage Liver Disease score greater than 32, combined

232 ikely to be used in recipients with model of end-stage liver disease score higher than 27 (13.2% vs.

233 , CDI was associated with having a model for end-stage liver disease score of 20 or greater (hazards

234 I was 50.16 +/- 11.7 years with a mean Model End-Stage Liver Disease score of 22.6 +/- 9.8.

235 Child class A (87%) with a median Model for End-Stage Liver Disease score of 8 (range 6-15).

236 ents with cirrhosis and with worse Model for End-Stage Liver Disease score or diabetes, those taking

237 Model for End-Stage Liver Disease score pretransplantation and the

238 Median preoperative model for end-stage liver disease score was 12.

239 s 50.2 +/- 8.5 years, and the mean model for end-stage liver disease score was 12.2 +/- 4.6.

240 The mean Model for End-Stage Liver Disease score was 14.5 +/- 4.

241 Model for End-Stage Liver Disease score was 15 (IQR, 11-21); cold

242 The Model for End-Stage Liver Disease score was lower in the DCD SLK g

243 The baseline Model for End-Stage Liver Disease score was not predictive of long

244 The median model for end-stage liver disease score was similar between the ge

245 renal function and lower baseline Model for End-Stage Liver Disease score were associated with bette

246 used in Donor Risk Index with the model for end-stage liver disease score yields an AUC-ROC of 0.764

247 mean Child Pugh, 7 +/- 3; and mean model for end-stage liver disease score, 13 +/- 6) completed the p

248 (mean age, 56 years; 61% men; mean model for end-stage liver disease score, 19.5).

249 ss index, hepatitis C virus (HCV), model for end-stage liver disease score, and acute rejection; and

250 al syndrome, dialysis requirement, model for end-stage liver disease score, and alcoholic liver disea

251 rity, indicated by a higher median Model for End-Stage Liver Disease score, and associated with incre

252 model based on comorbidity burden, Model for End-Stage Liver Disease score, and serum level of albumi

253 ence regarding cold ischemia time, model for end-stage liver disease score, and steatosis.

254 ) recipients, the weighting of the model for end-stage liver disease score, and the increased prevale

255 chniques identified recipient age, Model for End-Stage Liver Disease score, body mass index, diabetes

256 tion, controlling for age, gender, Model for End-Stage Liver Disease score, Child-Pugh score, serum s

257 ting in transplantation at a lower model for end-stage liver disease score, decreased death on waitli

258 ere PPIs, development of overt HE, Model for End-Stage Liver Disease score, low sodium, and age.

259 ferent age groups who had the same Model for End-Stage Liver Disease score.

260 ts in both groups had similar age, model for end-stage liver disease score.

261 of 28-day mortality together with Model for End-Stage Liver Disease score.

262 l group, from baseline (P = .001); Model for End Stage Liver Disease scores were reduced by 40.4% and

263 0.03) compared to those with lower Model of End-Stage Liver Disease scores (</=15).

264 iver transplant recipients with low model of end-stage liver disease scores (<27), without hepatitis

265 patients requiring DC had greater Model for End-stage Liver Disease scores (33 vs 27; P < .001); mor

266 fter LT was associated with higher model for end-stage liver disease scores and receiving a LT from a

267 plantation network so that patient model for end-stage liver disease scores at transplant is more uni

268 Renal impairment and high model of end-stage liver disease scores before liver transplantat

269 Pediatric End-Stage Liver Disease scores decreased from 16 +/- 4.6

270 maintained at 6 months; Child and Model for End-Stage Liver Disease scores did not change.

271 needed to calculate Child-Pugh and Model for End-Stage Liver Disease scores were recorded.

272 had significantly lower laboratory model for end-stage liver disease scores, pretransplant alpha feto

273 e North American Consortium for the Study of End-Stage Liver Disease sites from 2015 through 2017 (me

274 Cancer stage D ( P < .001), higher Model for End-Stage Liver Disease Sodium scores ( P < .001), highe

275 Adjusting for sex, age, Model for End-Stage Liver Disease, sodium, and Charlson index, the

276 L) mortality is adjudicated by the Model for End Stage Liver Disease-Sodium (MELD-Na) score.

277 f patients with cirrhosis have low Model for End Stage Liver Disease-Sodium (MELD-Na) scores, however

278 the discriminative ability of LFI+Model for End Stage Liver Disease-sodium (MELDNa) versus MELDNa al

279 which may not be reflected by the Model for End-Stage Liver Disease-Sodium (MELD-Na) score.

280 f patients with cirrhosis have low Model for End-Stage Liver Disease-Sodium (MELD-Na) scores; however

281 or End-Stage Liver Disease (MELD), Model for End-Stage Liver Disease-Sodium MELD-Na, and Child-Turcot

282 it is not clear which of these low Model for End-Stage Liver Disease-Sodium score patients would bene

283 ed significant after adjusting for model for end-stage liver disease-sodium score, mechanical ventila

284 However, patients with low Model for End-Stage Liver Disease-Sodium scores still suffer from

285 lications to the development of fibrosis and end-stage liver diseases, such as cirrhosis and hepatoce

286 ollowing the implementation of the model for end-stage liver disease system for liver transplantation

287 virus (HCV) infection is a leading cause of end-stage liver disease that necessitates liver transpla

288 In patients with end-stage liver disease, the ability to predict recovery

289 s well-recognized phenomena in patients with end-stage liver disease, the impact of gut dysbiosis and

290 nd Edinburgh with a United Kingdom Model for End-Stage Liver Disease (UKELD) score >=62 were register

291 usting for significant covariates (Model for End-Stage Liver Disease, vasopressor use).

292 riate analysis recipient age, sex, model for end stage liver disease, viral etiology had no bearing o

293 ude neonatal onset with rapid progression to end-stage liver disease, vitamin K-independent coagulopa

294 osis among DILI patients using the Model for End-Stage Liver Disease was improved by incorporation of

295 shock, hepatic encephalopathy and model for end stage liver disease were significantly different amo

296 full enteral feeding developed cirrhosis and end-stage liver disease, which require liver transplanta

297 f cirrhosis and hepatic failure resulting in end stage liver disease with limited pharmacological opt

298 The median Model for End-Stage Liver Disease with Sodium (MELD-Na) score was

299 HCV infection is one of the major causes of end-stage liver disease worldwide.

300 ed: age, female sex, lactate value, Model of End-Stage Liver Disease XI score, history of atrial fibr